Compare Organon & Co. Common Stock (OGN) vs Royal Caribbean Cruises Ltd (RCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Royal Caribbean Cruises Ltd — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Royal Caribbean Cruises Ltd trades at $275 (market cap $75.29B). The key difference: Royal Caribbean Cruises Ltd is far larger — about 20.8× Organon & Co. Common Stock's market cap, and Royal Caribbean Cruises Ltd pays the higher dividend (2.13%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Royal Caribbean Cruises Ltd for 85 Days on average.
| OGN | RCL | |
|---|---|---|
Market Cap | $3.62B | $75.29B |
Volume | 2,892,999 | 1,401,290 |
Sector | Health | Consumer Cyclical |
52-Week High | $13.81 | $348.03 |
52-Week Low | $5.70 | $230.30 |
Typical Hold Time | 0 Days | 85 Days |
Enterprise Value | $11.04B | $97.93B |
Dividend Yield | 0.58% | 2.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Royal Caribbean (RCL) trades at $281.51, up 0.3% with a bullish technical signal. The company shows strong fundamental momentum with Q1 and Q2 2026 earnings beats, robust profitability (23.5% net margin), and improving cash flow. Recent news highlights a $3 billion Sandals Resorts acquisition expanding into the resort market. Technical indicators show the stock trading near pivot point resistance at $285 with strong support at $276.
RCL presents a compelling growth story with accelerating revenue and earnings, though faces execution risks from the Sandals integration and fuel cost pressures. Analyst consensus remains bullish with a $344 price target representing 22% upside potential. The stock's premium valuation (P/E 17.4) appears justified by strong ROE (45.3%) and consistent earnings outperformance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Royal Caribbean Cruises Ltd
Royal Caribbean is the world's second-largest cruise company, operating 64 ships across five global and partner brands in the cruise vacation industry, with 10 more ships on order. Brands the company operates include Royal Caribbean International, Celebrity Cruises, and Silversea. The company also has a 50% investment in a joint venture that operates TUI Cruises and Hapag-Lloyd Cruises, allowing it to compete on the basis of innovation, quality of ships and service, variety of itineraries, choice of destinations, and price. The company completed the divestiture of its Azamara brand in the first quarter of 2021.
Read more on RCL →
